Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications [Seguridad de los anticuerpos monoclonales anti-CGRP en pacientes con migraña durante la pandemia de COVID-19: implicaciones actuales y futuras]

Caronna, E. ; José Gallardo, V. ; Alpuente, A. ; Torres-Ferrus, M. ; Sánchez-Mateo, N.M. ; Viguera-Romero, J. ; López-Veloso, A.C. ; López-Bravo, A. ; Gago-Veiga, A.B. ; Irimia Sieira, P. ; Porta-Etessam, J. ; Santos-Lasaosa, S. (Universidad de Zaragoza) ; Pozo-Rosich, P. ; Spanish, CGRP-COVID, Study, Group

Resumen: Background and objective: CGRP, a neuropeptide involved in migraine pathophysiology, is also known to play a role in the respiratory system and in immunological conditions such as sepsis. We analyzed the impact of the use of CGRP antagonists in patients with migraine during the COVID-19 pandemic, caused by the SARS-CoV-2 coronavirus. Methods: This is a multicentre cross-sectional study. From May to November 2020, through a national survey distributed by the Spanish Society of Neurology, we collected data about the presence of COVID-19 symptoms including headache and their characteristics and severity in patients with migraine treated with anti-CGRP monoclonal antibodies (mAb), and compared them with patients with migraine not receiving this treatment. We also conducted a subanalysis of patients with COVID-19 symptoms. Results: We recruited 300 patients with migraine: 51.7% (155/300) were taking anti-CGRP mAbs; 87.3% were women (262/300). Mean age (standard deviation) was 47.1 years (11.6). Forty-one patients (13.7%) met diagnostic criteria for COVID-19, with no statistically significant difference between patients with and without anti-CGRP mAb treatment (16.1% vs 11.0%, respectively; P = .320). Of the patients with COVID-19, 48.8% (20/41) visited the emergency department and 12.2% (5/41) were hospitalised. Likewise, no clinical differences were found between the groups of patients with and without anti-CGRP mAb treatment. Conclusion: Anti-CGRP mAbs may be safe in clinical practice, presenting no association with increased risk of COVID-19.

Idioma: Inglés

DOI: 10.1016/j.nrl.2021.03.003

Año: 2021

Publicado en: Neurología (Barcelona) 36 (2021), 611-617
ISSN: 0213-4853

Factor impacto JCR: 5.486 (2021)

Categ. JCR: CLINICAL NEUROLOGY rank: 46 / 212 = 0.217 (2021) - Q1 - T1

Factor impacto CITESCORE: 4.7 - Medicine (Q2)

Factor impacto SCIMAGO: 0.55 - Neurology (clinical) (Q2) - Medicine (miscellaneous) (Q2)

Tipo y forma: Article (Published version)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)